Table 1.
Group differences in clinical characteristics and neuropsychological assessment
| Characteristic | Patients Treated After Chemotherapy (n = 19) | Healthy Controls (n = 20) | P | ||
|---|---|---|---|---|---|
| Mean or Count | SD | Mean or Count | SD | ||
| Age (years) | 43.8 | 6.4 | 50.1 | 2.5 | 0.001 |
| Education (years) | 13.9 | 2.2 | 13.3 | 2.3 | 0.435 |
| Breast cancer stage (0, I, II, III, IV) | (0, 2, 14, 3, 0) | N/A | N/A | N/A | N/A |
| Chemotherapeutic drugs (Taxotere and Epirubicin) | 19 | N/A | N/A | N/A | N/A |
| Radiation therapy | 4 | N/A | N/A | N/A | N/A |
| Hormonal treatment | 1 | N/A | N/A | N/A | N/A |
| Menopausal | 5 | N/A | 5 | N/A | N/A |
| MMSE | 28 | 1.283 | 28.316 | 1.453 | 0.508 |
| CAMS-R | 33.882 | 4.471 | 33.895 | 3.972 | 0.993 |
| IES-R | 15.941 | 24.055 | 7.079 | 10.498 | 0.187 |
| Hospital Anxiety and Depression Scale (HADS) | |||||
| Anxiety | 7.118 | 5.075 | 6.474 | 3.485 | 0.666 |
| Depression | 3.941 | 3.842 | 5.474 | 2.702 | 0.184 |
| Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) | |||||
| Perceived cognitive impairments | 52.588 | 10.319 | 58.789 | 7.522 | 0.052 |
| Comments from others | 13.765 | 2.438 | 14.158 | 1.954 | 0.606 |
| Perceived cognitive abilities | 17.882 | 4.523 | 18 | 5.4 | 0.946 |
| Impact on quality of life | 11.765 | 3.557 | 14.211 | 1.989 | 0.023 |